Navigation Links
MitraClip(R) Therapy Data Demonstrate Clinical Benefit in High-Risk Patients With Mitral Regurgitation
Date:5/20/2009

EVEREST High-Risk Registry Data Show Improved Symptomatic Status, Cardiac Function and Reduced rate of Hospitalization for Congestive Heart Failure in both Functional and Degenerative MR Patient Populations

BARCELONA, Spain, May 20 /PRNewswire/ -- Results show percutaneous mitral repair using the MitraClip(R) system in symptomatic high-risk surgical patients with either functional mitral regurgitation (FMR) or degenerative mitral regurgitation (DMR) improves patient clinical status. The results from the 78 patient EVEREST II High Risk Registry demonstrated improvement in left ventricular function and reduced hospitalization for congestive heart failure for both MR groups at twelve months. Additionally, a reduction in mortality compared to the predicted mortality risk of surgery was reported for the registry. The results of the High-Risk Registry were presented today at the third annual meeting of EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

MR is the most common type of heart valve insufficiency in Europe and the United States, affecting millions of people worldwide. Significant MR affects more than eight million people in the US and Europe, the majority of which have FMR. There are more than 600,000 new diagnoses of significant MR each year in Europe and the US; however only 20 percent of these patients undergo surgery each year. Many higher risk surgical patients and non-surgical patients continue to be affected by the chronic volume overload caused by MR, which requires the heart to work harder, and may ultimately lead to heart failure.

The data were presented today by Saibal Kar, M.D., director of interventional cardiac research at Cedars-Sinai Medical Center and the lead enrolling investigator of the EVEREST trials.

"The High Risk Registry data support our belief that the MitraClip therapy is a safe and clinically bene
'/>"/>

SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
2. First Swiss Patients Treated with the Percutaneous MitraClip(R) System
3. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
4. First European Patients Treated With the Percutaneous MitraClip(R) System
5. New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation
6. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
7. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
8. CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy
9. New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
10. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
11. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
(Date:11/21/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced ... will be presenting at the 26 th Annual Piper ... New York . The formal presentation is ... In addition, Mr. Krakauer and Jorgen B. Hansen , ... during the day. An audio webcast will ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
... Janssen Pharmaceuticals, Inc. today announced the results ... ER (tapentadol) extended-release tablets were significantly more effective ... with chronic moderate to severe, painful diabetic peripheral ... at the 31st Annual Scientific Meeting of the ...
Cached Medicine Technology:Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
(Date:11/22/2014)... November 23, 2014 Today, Dylan Queen, ... new collection of wedding dresses; the business offers a ... related accessories for ladies worldwide, allowing them to create ... of the company, this new collection of chic wedding ... Moreover, they are offered at discounted rates now. Dylan ...
(Date:11/22/2014)... 22, 2014 Discount-Dress.com is an ... the firm is to increase the company’s online market share ... new selection of bridesmaid dresses and announced a bridesmaid dress ... valid until Dec. 30, 2014. All the dresses from this ... , In fact, Discount-Dress.com is very good at manufacturing ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 "My friend ... pain caused by the machine," said an inventor from ... had to go back a second time because the ... idea." , She developed the patent-pending MAMO EASY to ... cancer. The design saves the patient from the pain ...
(Date:11/22/2014)... The wide variety and complexity of foods served at ... food allergies, an expert warns. "Every person is ... allergies that it can be really difficult to avoid ... of allergy and clinical immunology at Wake Forest Baptist ... "If you know you have food allergies, caution should ...
(Date:11/22/2014)... This month has been a historical time for Angeldress.co.uk, ... positive reviews from some renowned review websites. Recently, the company ... a new selection of wonderful sexy wedding dresses to its ... shipping and up to an 80% discount on any order ... the most suitable dress at Angeldress.co.uk, which has garnered a ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2
... metalloproteinase 1 and vitamin D synthesis may determine the ... ,The researchers analysed genetic variations in 312 people, just ... replacement in the 10 years following surgery. ... 'aseptic loosening,' which describes a condition in which the ...
... March 14 (IANS) India Wednesday launched a major initiative ... NGO// in Tamil Nadu planning a usage study in ... with the Hindustan Latex Ltd and the National Aids ... to provide female condoms at just Rs.3 to NGOs ...
... move could force pharmaceutical companies into a reformulation drive ... flu products// that do not contain the restricted ingredients. ... letter seeking opinion on the proposed restrictions, which would ... reduction in pack size by the end of 2007. ...
... pressure could certainly be an indicator of one’s happiness. Researchers ... between a nation's overall happiness and its citizens' blood pressure ... people from across the European countries. ,These people were asked ... hypertension (high blood pressure) and so on. ,While ...
... Brasilia – Svelte models have lent their charm in the many ... enviable trend//, a recent survey has painted a different picture of ... thought to be and the men drink far too much. Nearly ... over weight category, the survey revealed. ,Sao Paulo, the ...
... discovered a new type of cells, which they say appear ... ,The medical team led by Jian-Xin Gao at Ohio ... or pCSCs, that can either remain benign or become malignant, ... cells are very complex. They have properties of normal and ...
Cached Medicine News:Health News:India to Market Female Condoms 2Health News:UK to Pull Pseudoephedrine 2Health News:UK to Pull Pseudoephedrine 3
... reliable strength for temporary wound support. ... compliant and stretchable support material is ... is not required. Predictable absorption. Polyglactin ... inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... is designed for the repair of abdominal ... that has two distinct sides. One ... a layer of sodium hyaluronate and carboxymethylcellulose ... This coated side is bioresorbable, providing a ...
... Human explant studies have confirmed ... for maximum clinical performance in hernia ... Atriums thinner and less dense hernia ... less rigid repair. Since 1994, when ...
Medicine Products: